Cannabidivarin [CBDV]

Chemical and Physical Data

• Cannabidivarin (CBDV) is a non-intoxicating psychoactive cannabinoid found in Cannabis.
• CBDV is a homolog of cannabidiol (CBD), with the side-chain shortened by two methylene bridges (CH units).
• Enhanced levels of CBDV have been reported in feral populations of C. indica from northwest India and in hashish from Nepal.
• CBDV demonstrated anticonvulsant properties in rodent models in a single published study.
• CBDV has seven double bond isomers and 30 stereoisomers and is not scheduled by the Convention on Psychotropic Substances.

GW Pharmaceuticals Development

• CBDV is actively being developed by GW Pharmaceuticals as GWP42006.
• GW Pharmaceuticals has initiated several Phase-2 trials for adult epilepsy, childhood epilepsy, and Prader-Willi Syndrome.
• CBDV has shown a neurochemical pathway for anti-epileptic and anti-convulsive action.
• Preliminary results of a Phase 2a study for GWP42006 were announced by GW Pharmaceuticals.
• A Phase 2 clinical study of CBDV in epilepsy was initiated by GW Pharmaceuticals.

Research and Studies

• Turner et al. conducted a study on the constituents of Cannabis sativa, including CBDV.
• Hillig and Mahlberg analyzed cannabinoid variation in Cannabis.
• Merkus identified cannabivarin and tetrahydrocannabivarin as constituents of hashish.
• Hill et al. found that CBDV is anticonvulsant in mouse and rat models.
• Vollner et al. were the first to identify CBDV in 1969.

Related Articles and Publications

• A list of investigational analgesics is available for further reference.
• Various studies and publications have explored the chemical profile and effects of CBDV.
• GW Pharmaceuticals’ press releases and announcements provide updates on CBDV research and development.
• NSW provided advice to practitioners on Medical Cannabis trials.
• The article on CBDV is a stub on Wikipedia, inviting expansion and contributions.

Potential Medical Applications

• CBDV has shown promise as an anticonvulsant in preclinical studies.
• Research suggests CBDV may suppress epilepsy-related gene expression.
• CBDV is being investigated for its potential in treating epilepsy, particularly in Phase 2 trials.
• The preliminary results of CBDV studies indicate its efficacy in managing epilepsy.
• CBDV may offer new treatment options for epilepsy and related conditions.

Cannabidivarin Data Sources